Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals has received a clean Annual Secretarial Compliance Report from M/s. Mehta & Mehta, Company Secretaries, for FY 2025-26. The report examines compliance across multiple SEBI regulations including LODR, ICDR, SAST, PIT, and SCRA. The auditors found zero deviations or violations — the company maintained full compliance with all applicable regulations throughout the review period. No actions were taken by SEBI or stock exchanges against the company. All 13 compliance checkpoints including secretarial standards, board composition, related party transactions, website disclosures, and insider trading norms were marked compliant. The company also had no pending observations from prior year reports.
A clean compliance report with no deviations or regulatory actions is positive for shareholders as it indicates strong corporate governance and reduces investment risk. This filing, while routine, confirms the company operates within SEBI regulatory requirements without any flagged issues.